Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2010-04-06 Audit Report / Informat…
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
8-K/A Filing
Audit Report / Information Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, specifically reporting a change in the company's independent registered public accounting firm. It details the termination of Holtz Rubenstein Reminick LLP as the auditor and the engagement of Deloitte & Touche LLP for the next fiscal year. The document includes disclosures required by Item 304(a) of Regulation S-K regarding disagreements and reportable events with the former auditor. It also attaches a letter from the former auditor agreeing with the statements made. This type of filing is a regulatory announcement about changes in auditors and related audit information, which fits the category of Audit Report / Information (AR). The document is not the full audit report itself but provides detailed audit-related disclosures and updates on auditor changes, which aligns with the AR category rather than a general regulatory filing or report publication announcement. The document length (5532 characters) supports it being a substantive filing rather than a brief announcement. Therefore, the classification is AR with high confidence.
2010-04-06 English
8-K Filing
Regulatory Filings
2010-04-01 English
10-K Filing
Annual Report FY 2009
2010-03-31 English
3 Filing
Director's Dealing
2010-03-30 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an entry into a material definitive agreement regarding warrants and amendments to warrant terms. It includes details about the transaction, board approval, and related party information. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, call transcript, or governance report. It is a regulatory filing announcing a material event related to capital structure but not a direct capital/financing update like a fundraising announcement. Given the nature of Form 8-K filings and the content, the best classification is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories. The document length is under 5,000 characters, but it is not merely announcing a report publication; it contains substantive event disclosure. Therefore, RNS is appropriate with high confidence.
2010-03-18 English
4 Filing
Director's Dealing
2010-03-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.